ALK and bone metastasis: Cox multivariate analysis showed that no smoking habit (hazard ratio [HR], 0.494; 95% CI, 0.258–0.946; p = 0.034), no bone metastasis (HR, 0.502; 95% CI, 0.295–0.854; p = 0.011), administration of second‐generation ALK inhibitors (HR, 0.584; 95% CI, 0.369–0.922; p = 0.021) and third‐generation ALK inhibitors (HR, 0.250; 95% CI, 0.115–0.547; p = 0.001) were related to longer OS (Table 2).